This white paper focuses on recent consumer openness towards clinical research and how it represents an exciting opportunity for the biopharma industry to engage with patient communities and accelerate research.
Finding a partner to perform your AME studies in a reasonable time frame, let alone one with an excellent track record, may be a challenge. Discover how these challenges can be overcome in the available white paper.
Patient enrollment can vary widely within regions, countries and sites due to competitive enrollment and other variables. This unpredictability introduces risk into the supply chain. Learn why it is critical to be aware of these risks and understand how best to mitigate them within trials.
Discover how bringing a modified version of an existing drug to market through 505(b)(2) can offer a clear path to approval, a differentiated product, and at least some period of marketing exclusivity.
Even though everyone applauds the renewed focus on patients as a positive development, some say it is time for biopharma companies to turn their attention to another audience: clinical trial participants.